The inhibitory effects of rh-endostatin (YH-16) in combination with radiotherapy on lung adenocarcinoma A549 in mice and the underlying mechanisms

Journal of Huazhong University of Science and Technology - Medical Science

Volumn 30, Issue 1, 2010, Pages 108-112

  Wu, Huita ^a   Deng, Jie ^b   Yu, Shiying ^b   Wang, Xin ^a   Chen, Yuan ^b  

^a XIAMEN UNIVERSITY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Human lung adenocarcinoma cell line A549; Lung neoplasms; Radiotherapy; Recombinant human Endostatin; Xenografted tumor

Indexed keywords

ANGIOGENESIS INHIBITOR; ENDOSTAR PROTEIN; ENDOSTATIN; FIBROBLAST GROWTH FACTOR 2; MESSENGER RNA; RECOMBINANT PROTEIN; VASCULOTROPIN A;

ADENOCARCINOMA; ANIMAL; ARTICLE; DOWN REGULATION; DRUG SCREENING; GENETICS; HUMAN; LUNG TUMOR; METABOLISM; MOUSE; MULTIMODALITY CANCER THERAPY; NUDE MOUSE; PATHOLOGY; RADIOTHERAPY; TUMOR CELL LINE;

ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; ANIMALS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DOWN-REGULATION; ENDOSTATINS; FIBROBLAST GROWTH FACTOR 2; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; RADIOTHERAPY; RECOMBINANT PROTEINS; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77149180770     PISSN: 16720733     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11596-010-0120-6     Document Type: Article

References (20)

1. S. Tyldesley C. Boyd K. Schiclze, et al. 2001 Estimating the need for radiotherapy for lung cancer: an evidence-based, epidemiologic approach Int J Radiat Oncol Biol Phys 49 4 973 985 10.1016/S0360-3016(00)01401-2 1:STN:280:DC%2BD3M7osFajtQ%3D%3D 11240238 (Pubitemid 32184604)
2. Y. Mizukami Y. Kohgo D.C. Chung, et al. 2007 Hypoxia inducible factor-1 independent pathways in tumor angiogenesis Clin Cancer Res 13 19 5670 5674 10.1158/1078-0432.CCR-07-0111 1:CAS:528:DC%2BD2sXhtFSntLzL 17908955 (Pubitemid 47583891)
3. M.I. Koukourakis A. Giatromanolaki E. Sivridis, et al. 2001 Squamous cell head and neck cancer: evidence of angiogenic regeneration during radiotherapy Anticancer Res 21 6B 4301 4309 1:STN:280:DC%2BD387ns1Kmtg%3D%3D 11908684
4. M. Ziche A. Parenti F. Ledda, et al. 1997 Nitric oxide promotes proliferation and plasminogen activator production by coronary venular endothelium through endogenous bFGF Circ Res 80 6 845 852 1:CAS:528: DyaK2sXjsFaqsLY%3D 9168787
5. S.T. Ohnishi T. Ohnishi K. Nishino, et al. 2005 Growth inhibition of cultured human liver carcinoma cells by Ki-energy (Life-energy): Scientific evidence for Ki-effects on cancer cells Evid Based Complement Alternat Med 2 3 387 393 10.1093/ecam/neh116 16136218 (Pubitemid 41253352)
6. M.S. O'Reilly T. Boehm Y. e. a1. Shing 1997 Endostatin: An endogenous inhibitor of angiogensis and tumor growth Cell 88 2 277 285 10.1016/S0092- 8674(00)81848-6 9008168 (Pubitemid 28015876)
7. J.W. Wang Y. Sun Y.Y. Liu, et al. 2005 Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients Chin J Lung Cancer (Chinese) 8 4 283 290
8. C.G. Lee M. Heijn E. di Tomaso, et al. 2000 Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions Cancer Res 60 19 5565 5570 1:CAS:528:DC%2BD3cXns1ehtL4%3D 11034104
9. R.K. Jain 1988 Determinants of tumor blood flow: a review Cancer Res 48 10 2641 2658 1:STN:280:DyaL1c7psVeisQ%3D%3D 3282647
10. R.K. Jain 1999 Transport of molecules, particles, and cells in solid tumors Annu Rev Biomed Eng 1 241 263 10.1146/annurev.bioeng.1.1.241 1:CAS:528:DyaK1MXnvFyit7c%3D 11701489
11. R.K. Jain 2001 Normalizing tumor vasculature with anti-angiogenictherapy: a new paradigm for combination therapy Nat Med 7 9 987 989 10.1038/nm0901-987 1:CAS:528:DC%2BD3MXmvFOmsrc%3D 11533692 (Pubitemid 32937367)
12. G. Bowers D. Reardon T. Hewitt, et al. 2001 The relative role of ErbB1-4 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cells Oncogene 20 11 1388 1397 10.1038/sj.onc.1204255 1:CAS:528:DC%2BD3MXisFWgsrg%3D 11313882 (Pubitemid 32269943)
13. J. Brieger P. Schroeder J. Gosepath, et al. 2005 Vascular endothelial growth factor and basic fibroblast growth factor are released by squamous cell carcinoma cells after irradiation and increase resistance to subsequent irradiation Int J Mol Med 16 1 159 164 1:CAS:528:DC%2BD2MXmt1Cmurw%3D 15942693
14. D.S. Gridley R.B. Bonnet D.A. Bush, et al. 2004 Time course of serum cytokines in patients receiving proton or combined photon/proton beam radiation for resectable but medically inoperable non-small cell lung cancer Int J Radiat Oncol Biol Phys 60 3 759 766 1:CAS:528:DC%2BD2cXotFCmtLw%3D 15465192
15. R.C. Reis D. Schuppan A.C. Barreto, et al. 2005 Endostatin competes with bFGF for binding to heparin-like glycosaminoglycans Biochem Biophys Res Commun 333 3 976 983 10.1016/j.bbrc.2005.06.011 1:CAS:528:DC%2BD2MXlvVentbo%3D 15985216 (Pubitemid 40854252)
16. Y.L. Chung J.J. Jian S.H. Cheng, et al. 2006 Sublethal irradiation induces vascular endothelial growth factor and promotes growth of hepatoma cells: implications for radiotherapy of hepatocellular carcinoma Clin Cancer Res 12 9 2706 2715 10.1158/1078-0432.CCR-05-2721 1:CAS:528:DC%2BD28Xltlams7s%3D 16675562 (Pubitemid 43752108)
17. Y. Ling Y. Yang N. Lu, et al. 2007 Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells Biochem Biophys Res Commun 361 1 79 84 10.1016/j.bbrc.2007.06.155 1:CAS:528:DC%2BD2sXotlWru7k%3D 17644065
18. I. Zachary 1998 Vascular endothelial growth factor Int J Biochem cell Biol 30 11 1169 1174 10.1016/S1357-2725(98)00082-X 1:CAS:528:DyaK1cXnsFSrt7w%3D 9839443 (Pubitemid 28515661)
19. H.J. Mauceri N.N. Hanna M.A. Beckett, et al. 1998 Combined effects of angiostatin and ionizing radiation in antitumour therapy Nature 394 6690 287 291 10.1038/28412 1:CAS:528:DyaK1cXkvVKju74%3D 9685160 (Pubitemid 28335042)
20. B.A. Teicher S. A. Holden G. Ara, et al. 1995 Influence of an anti-angiogenic treatment on 9L gliosarcoma: oxygenation and response to cytotoxic therapy Int J Cancer 61 5 732 737 10.1002/ijc.2910610523 1:CAS:528:DyaK2MXms1Smtbg%3D 7768649